A self-assembling peptide disrupts liver cancer lysosomes, helping lenvatinib and other therapies work better in mouse models without reformulating the drugs.
(Nanowerk Spotlight) A potent cancer drug can still fail if biology sends it to the wrong place. After entering the body, a therapy must travel through tissue, enter cancer cells, and reach the vulnerable structures inside them. At each step, the body or the tumor cell can divert it.
One major diversion occurs after the drug has already entered a cancer cell. Cells contain small compartments that sort, recycle, and break down material. Lysosomes are among the most important of these compartments. In liver cancer, they can trap drugs in acidic recycling spaces or help tumor cells survive stress through autophagy, the cell’s recycling program.
The design combines tumor targeting with a triggered structural change. One segment guides the peptide toward hepatocellular carcinoma cells. A hydrophobic segment helps it form nanospheres under neutral conditions. A fiber-forming segment drives the switch into nanofibers under lysosome-like conditions. The design aims beyond tumor entry. It targets the compartment that often weakens therapy after uptake.
The engineered RS-FS peptide combines a liver cancer-targeting segment with nanosphere-forming and fiber-forming segments. It is designed to stay compact under blood-like conditions, then switch into lysosome-disrupting nanofibers inside acidic, reducing lysosomes, helping trapped therapies escape and act inside the cell. (Image: Adapted with permission from Wiley-VCH Verlag)
The first requirement was controlled shape change. Under neutral and mildly acidic environments, the peptide stayed in nanosphere form, with an average size of 147 nm. Under lysosome-like acidity and glutathione levels, it shifted into fibers and hydrogel-like networks. Control peptides lacking the complete design did not show the same behavior, which supports the role of the full peptide structure.
Shape change alone was not enough. The peptide also had to damage lysosomes mainly in cancer cells. In human liver cancer cells, RS-FS made lysosomes swell and leak cathepsin B, a marker of lysosomal membrane damage. Normal human liver cells showed much weaker effects. In mouse tumor models, labeled RS-FS accumulated more selectively in tumors than a scrambled peptide.
RS-FS was not inert without a drug. In the reported cell tests, it reduced tumor cell growth through lysosome disruption while showing minimal effects on normal liver cells. That result separates the peptide from a conventional carrier. It does not only transport a therapy. It changes the intracellular conditions that can help tumor cells resist treatment.
To see whether lysosome disruption improved drug release, the researchers turned to doxorubicin, a fluorescent chemotherapy that can be tracked inside cells. The experiment showed whether RS-FS helped move drug cargo out of lysosomes and into the nucleus, where doxorubicin damages DNA. In this study, doxorubicin served mainly as a model for delivery and lysosomal escape.
In orthotopic liver cancer mice, where tumors grew in the liver, RS-FS-doxorubicin reduced tumor weight about 40-fold compared with free doxorubicin. The formulation also reduced measured toxicity in mice. Free doxorubicin caused weight loss and signs of heart, liver, and kidney damage at high doses, while RS-FS-doxorubicin reduced those off-target effects in the study’s assays.
The study’s most relevant therapeutic test used lenvatinib, an oral multi-kinase inhibitor used for hepatocellular carcinoma. Lenvatinib can stimulate autophagic flux, a lysosome-dependent recycling pathway that may reduce its antitumor effect. The researchers did not package lenvatinib inside RS-FS. They kept lenvatinib oral and gave the peptide intravenously, using RS-FS as a separate adjuvant.
Keeping the drug and peptide separate matters because it avoids redesigning lenvatinib itself. In subcutaneous liver cancer mice, RS-FS plus lenvatinib reduced tumor volume 47-fold compared with lenvatinib alone. In orthotopic liver cancer mice, the combination reduced tumor weight 61-fold compared with lenvatinib alone. MRI showed no detectable tumors in half of the treated animals at the study endpoint.
The cellular evidence fit the proposed mechanism. Tumor cells treated with RS-FS and lenvatinib lost visible lysosome pools and accumulated damaged mitochondria. The researchers also observed cytochrome c release, higher apoptosis markers, and lower Ki67, a marker of cell proliferation. These results support the interpretation that RS-FS interferes with autophagic flux and makes lenvatinib-treated tumor cells more vulnerable.
A final set of experiments tested the peptide with a different therapeutic format. The researchers used extracellular vesicles from Epimedium brevicornu Maxim., a medicinal plant. These vesicles were enriched with icariin, which the researchers converted enzymatically into icaritin, an anti-HCC compound that the paper describes as clinically approved in China. Nanowerk has covered related interest in extracellular vesicles as targeted drug delivery systems.
This part of the study asked whether RS-FS could help a therapy that was not preloaded into the peptide. RS-FS helped the plant-derived vesicles escape lysosomes in liver cancer cells and strengthened their antitumor effect in orthotopic mouse models. Vesicles alone did not halt tumor growth. Oral vesicles combined with intravenous RS-FS shrank tumors and increased tumor cell death along with immune markers associated with stronger antitumor activity.
The result broadens the role of nanoscale design from transport to intracellular intervention. Earlier Nanowerk coverage of lysosome permeabilization as a route to cancer cell death also points to lysosomes as actionable intracellular targets. In the new work, the key trigger is not remote activation, but the lysosome’s own chemistry.
The results still sit firmly in the preclinical stage. The evidence comes from cultured cells and mouse models. Researchers still need broader safety studies, repeat-dose testing, immune profiling, manufacturing controls, and experiments across more diverse tumor settings. The peptide’s linear design may make synthesis comparatively practical, but that does not reduce the need for pharmacology and toxicity work.
The strategic shift is from merely escaping lysosomes to using their chemistry as a trigger. Many delivery systems try to escape lysosomes after entering cells. RS-FS instead treats tumor lysosomes as conditional targets, using their acidic and reducing chemistry to trigger disruptive self-assembly. In hepatocellular carcinoma models, that approach helped existing and experimental therapies by attacking a compartment that can protect tumor cells.
For authors and communications departmentsclick to open
Lay summary
Prefilled posts
Nanowerk Newsletter
Get our Nanotechnology Spotlight updates to your inbox!
Thank you!
You have successfully joined our subscriber list.
Become a Spotlight guest author! Join our large and growing group of guest contributors. Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Here is how to publish on nanowerk.com.
